Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Hong Kong Baptist University invents novel cell sensor for rapid and low-cost screening of drug-resistant bacteria

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 29 September 2021 - A research team led by scientists at Hong Kong Baptist University (HKBU) has developed a novel cell sensor with a barcode-like micro-channel structure that enables rapid and low-cost screening of drug-resistant bacteria. The invention could potentially be used on a large-scale in resource-limited situations such as frequent safety screenings of water, food and public facilities, as well as urgent surveys of massive samples during an infectious disease outbreak, particularly in developing countries. A research paper on the novel invention was published in the international academic journal Biosensors and Bioelectronics. A research team led by Dr Ren Kangning, Associate Professor of the Department of Chemistry at HKBU (left), designed a fully automatic, microscope-free antimicrobial susceptibility testing (AST) system. It enables rapid and low-cost screening of drug-resistant bacteria by scanning the "barcode" on the cell sensor with a mobile app, which is shown by Chan Chiu-wing, a member of the research team and a PhD student of the Department of Chemistry at HKBU (right). The cell sensor with a barcode-like micro-channel structure comprises two main parts: a cell culture zone and a "barcode" cell sensor. A rapid and low-cost testing approach Antibiotics are often used to treat bacterial infections, but the overuse and misuse of antibiotics have created the problem of drug resistance. Antimicrobial susceptibility testing (AST) is used to determine which antibiotics can effectively inhibit the growth of a certain type of bacteria effectively. However, conventional AST methods are too slow, as they require 16 to 24 hours for results, while modern rapid ASTs are expensive and require elaborated laboratory equipment. A rapid and cost-effective strategy is therefore needed to screen bacterial samples onsite, with advanced laboratory testing arranged only for those suspected of containing drug-resistant bacteria. In response to this need, a research team led by Dr Ren Kangning, Associate Professor of the Department of Chemistry at HKBU designed a fully automatic, microscope-free AST system. It comprises two main parts: a cell culture zone and a "barcode" cell sensor. The cell culture zone consists of a set of micro-channels filled with fluids that contain cell culture media as well as different concentrations of the antibiotic. The "barcode" cell sensor contains an array of "adaptive linear filters" arranged in parallel that resembles a "barcode" structure. Users can finish the onsite screening within three hours by scanning the "barcode" with a mobile app developed by the researchers, and it will indicate whether any drug-resistant pathogenic bacteria is present in the sample. Quantity of bacteria represented by bar length When conducting AST with the system, bacterial samples will be injected into and incubated in the cell culture zone. Bacteria in the test sample inside the micro-channels show different proliferation rates depending on different concentrations of the antibiotic. After completion of the culture period, the bacterial cells will flow through the "adaptive linear filters". The cells will not accumulate around the nanopores on the sidewalls of the micro-channels, instead they will be driven down by the fluid and be collected from the end of the micro-channels. The accumulated cells will then form visible vertical bars, the lengths of which are proportional to the quantity of bacteria cells cultured under the different concentrations of the antibiotic. A cell phone equipped with a macro-lens can then be used to photograph the "barcode" created by the AST. The image will be analysed automatically by the mobile app. Results consistent with conventional AST After the culture period, if all the "bars" of the cell sensor have similar lengths, it means the tested antibiotic cannot inhibit the growth of the bacteria, and thus the bacterial sample is resistant to the tested antibiotic. If the length of the "bars" is in general inversely proportional to the concentration of the antibiotic in the micro-channels, it shows that the tested antibiotic is generally effective at prohibiting the growth of the bacteria, and thus the bacteria is not drug-resistant. When two adjacent "bars" show a sharp difference in terms of length, it indicates that the antimicrobial effect of the antibiotic leaps when its concentration reaches a particular level. The research team tested E. coli and S. aureus with the "barcode" cell sensor and the results were consistent with those of the conventional AST. The test can be completed in three hours, which is much faster than the conventional AST. Microfluidic approaches developed by other researchers can also attain comparable speed, but they rely on expensive instruments for analysis in general. Potential for use in resource-limited regions "Our 'barcode' testing system is a promising new tool in the fight against antimicrobial resistance. We hope that it will benefit the routine screening of drug-resistant bacteria in the food industry, public areas and healthcare facilities as it does not require advanced clinical facilities or professional testing skills," said Dr Ren. The "barcode" cell sensor has a low production cost, and it is estimated to be below one US dollar per piece. The research team has filed a patent application for the "barcode" cell sensor. "We plan to develop our invention into a portable AST instrument, and ultimately, we hope it can be used in resource-limited regions," Dr Ren added. Apart from researchers from HKBU's Department of Chemistry, the research team of the "barcode" cell sensor also included scientists from the Department of Computer Science at HKBU and the School of Medicine at Stanford University. #HongKongBaptistUniversity #HKBU Contact Details Communication and Public Relations Office, HKBU Winnie Shum +852 3411 5262 winnieshum@hkbu.edu.hk Company Website https://www.hkbu.edu.hk/

September 29, 2021 09:00 AM Eastern Daylight Time

Image

ASPEN DENTAL TO PROVIDE FREE DENTAL CARE TO MILITARY VETERANS ON SATURDAY, NOVEMBER 6th

Aspen Dental

In recognition of Veterans Day, nearly 600 Aspen Dental locations will open their doors on Saturday, November 6 th to provide free care to military veterans across the country. Now in its 7 th year, the Day of Service provides much-needed dental care for veterans at no cost to honor their service and break down barriers to care. “The annual Day of Service is an incredibly rewarding day for dentists and teams throughout the Aspen Dental network,” said Dr. Lauren McDonough, vice president of practice owner development at Aspen Dental Management, Inc. “It’s our small way of giving back to our nation’s veterans, who have given so much to all of us.” Since 2014, dentists and their teams from Aspen Dental-branded offices across the country have donated more than $22 million in dentistry services to more than 27,500 veterans and people in need though the Healthy Mouth Movement. Millions of Americans struggle to access dental care every year, and veterans are no exception – in fact, U.S. veterans are ineligible for dental benefits through the Veterans Administration unless they’re 100% disabled, have a service-related mouth injury, or were a prisoner of war. What’s more, during the COVID-19 pandemic, dentists have report ed increases in teeth-grinding, cavities and gum disease, largely attributed to pandemic-related stress and changes in health habits. How Veterans Can Schedule an Appointment Starting today, veterans can call 1-844-277-3646 (1-844-ASPENHMM) to find a participating Aspen Dental office in their community and schedule an appointment. Advance appointments are required. During the Day of Service, Aspen Dental dentists and teams focus on treating the most urgent dental needs to help get veterans out of pain, from fillings and extractions to hygiene and basic denture repairs. For more information about Day of Service and the Healthy Mouth Movement, visit www.HealthyMouthMovement.com. About Aspen Dental Offices The Aspen Dental network includes more than 930 offices, in 43 states, owned and operated by independent practice owners and dentists, who share a commitment to creating access to care for those who need it most. These independent practice owners expect to record six million patient visits in 2021, driven by a commitment to breaking down barriers to quality, affordable oral health care. Each dental care team offers patients a safe, welcoming, judgment-free environment to address their dental challenges, including comprehensive exams, cleanings, extractions, fillings, periodontal treatment, whitening, oral surgery, crown and bridge work, and denture services. For more information, visit www.aspendental.com. About Aspen Dental Management, Inc. Aspen Dental Management, Inc. (ADMI) is one of the largest and most trusted retail healthcare business support organizations in the U.S., supporting 15,000 healthcare professionals and team members at more than 1,000 health and wellness offices across 46 states in three distinct categories: Dental care, urgent care, and medical aesthetics. Working in partnership with independent practice owners and clinicians, the team is united by a single purpose: to prove that healthcare can be better and smarter for everyone. ADMI provides a comprehensive suite of centralized business support services that power the impact of four consumer-facing businesses: Aspen Dental, ClearChoice Dental Implant Centers, WellNow Urgent Care and Chapter Aesthetic Studio. Each brand has access to a deep community of experts, tools and resources to grow their practices, and an unwavering commitment to delivering high-quality consumer healthcare experiences at scale. Contact Details Curley Company for Aspen Dental Management, Inc. Lorianne Walker +1 410-688-1330 lorianne@curleycompany.com

September 29, 2021 09:00 AM Eastern Daylight Time

Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics

Agile Therapeutics

Agile Therapeutics, Inc. (Nasdaq: AGRX ), a women's healthcare company, announced today a partnership with U.S. Women’s Soccer legend, Carli Lloyd. The partnership with Agile will focus on bringing awareness to women’s health topics, and Agile’s commitment to elevating women’s healthcare. Lloyd, who will play her final game for the U.S. Women’s National Team on October 26 th against South Korea, was attracted to the company’s mission of addressing the healthcare needs of today’s women. “I’m excited to be partnering with a company solely dedicated to women’s health,” said Lloyd. “I aim to work with organizations that focus on things I care about, and staying healthy has been a priority for my career on the field and will continue to be so as I look ahead to my next chapter. Agile’s focus on bringing women options and knowledge when it comes to their healthcare decisions is a mission I’m proud to be part of. And the fact that I’m a Jersey girl, representing a New Jersey company makes it even better.” Agile has built its brand around a commitment to addressing women’s health needs. It received approval from the U.S. Food and Drug Administration (FDA) in February 2020 for its first product, Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system, a weekly contraceptive patch. It currently has four additional contraceptive products in its pipeline. “Carli’s ‘ always believe and never quit ’ attitude fits what Agile Therapeutics believes as a company,” said Al Altomari, CEO of Agile Therapeutics. “We’ve been selective about aligning with the right partners at the right time, and Carli is someone who seamlessly fits our corporate culture, aligns with our values, and understands the importance of empowering women, especially young women, to reach beyond their limits, believe in themselves, and never compromise, especially with their healthcare.” As a growing company, Agile sees this partnership as an opportunity to help further develop its culture and corporate brand by partnering with leaders who share the company’s values and mission.. “Our short-term goal is to establish Twirla in the contraceptive market, and our long-term mission remains the same: Build a robust women’s health franchise, and Carli is a critical piece of that puzzle,” said Altomari. “She’s been a vocal advocate for women, and her voice is an important one in the national conversation about women’s health and healthcare needs. We want to be sure we communicate our message and commitment to women’s health in an authentic and relatable way. This is a mission we share with Carli, and we are proud to welcome her to our team.” About Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website. About Twirla® Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Twirla is indicated for use as a method of contraception by women of reproductive potential with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Healthcare providers (HCPs) are encouraged to consider Twirla’s reduced efficacy in women with a BMI ≥ 25 to <30 kg/m2 before prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg/m2. Twirla is contraindicated in women over 35 years old who smoke. Cigarette smoking increases the risk of serious cardiovascular events from CHC use. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch. Contact Details Matt Riley, Head of Investor Relations and Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com

September 28, 2021 02:52 PM Eastern Daylight Time

Data Show New Kidney and Liver Policies Expand Access, Equity

United Network for Organ Sharing

New liver and kidney allocation policies have expanded equitable access to lifesaving organs for patients on the national waitlist, according to data analysis from United Network for Organ Sharing (UNOS), which serves as the nation’s transplant system under federal contract. UNOS leadership presented this data for members of Congress during a virtual briefing today. Changes to the liver allocation policy went into effect in February of 2020 and the kidney allocation policy followed a year later, in March of 2021. Recent monitoring report data show the liver and kidney policies have so far resulted in more transplants overall while also reducing disparities in access based on where a patient is listed. Liver transplants increased by 3 percent and kidney transplants increased by 16 percent, even in the midst of the COVID-19 pandemic. This is in keeping with the high performance of the national donation and transplantation system, which marked the eighth year of growth in deceased donor transplants in 2020 despite the ongoing global health crisis. “These policies expand equitable access to lifesaving organs,” said UNOS CEO Brian Shepard. “We continue to make progress through robust policy development, improving the highest performing organ donation and transplantation system in the world.” The 15-month liver monitoring report shows that the policy is performing as intended. More organs are going to the sickest patients, especially adults with the most medically-urgent needs, regardless of where they are listed for transplant. Early monitoring data of the circles-based model for kidney allocation indicate that it has also contributed to broadened equity. A new report containing key measures of the first full two-months of enactment show an increase in kidney transplants for children, ethnic and racial minorities, moderately hard-to-match patients and those with longer dialysis times. More than 400 donation and transplant professionals, donor family members and patients nationwide helped develop the new policies. “The results of the new kidney and liver policies are a testament to our community’s ability to unify a diverse membership around the shared goal of saving lives,” said UNOS Board President Matt Cooper, M.D., Director of Pancreas and Kidney Transplantation at MedStar Georgetown Transplant Institute, and professor of surgery at Georgetown University School of Medicine. “Even during a pandemic, we saw a resilient system not only rebound, but formalize, enact, and monitor two effective allocation policies. UNOS is the engine that powers this complex process, and we remain focused on building on our successes while continuing to address ongoing challenges.” To learn more about UNOS’ policy development process, click here. ### About United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and follow the policies the OPTN creates for allocating organs. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

September 28, 2021 12:18 PM Eastern Daylight Time

BreatheSuite Receives FDA Clearance for Over-the-Counter Device to Turn Regular Metered-Dose Inhalers into Smart Inhalers

BreatheSuite

BreatheSuite Inc., a Canadian connected respiratory health company, today announced that it has received 510(K) clearance from the U.S. Food and Drug Administration (FDA) for its BreatheSuite Metered-Dose Inhaler (MDI) V1 device. Approved for both prescription and over-the-counter use, the BreatheSuite device turns existing MDIs into smart inhalers by automatically and objectively monitoring and providing feedback on inhaler adherence and technique for people with asthma and COPD. Tens of millions of Americans currently use MDIs. Techniques such as shaking the MDI 10-15 times, as well as breath timing and positioning, can greatly impact the amount of medication that reaches the lungs. For every 100 people who use an inhaler, 90 are using it incorrectly; 66 are not adherent to the medication as prescribed (skipping doses, etc.). Inhaler misuse makes up about $5- $7 billion of the approximately $25 billion spent on inhalers annually. The BreatheSuite System – composed of a disposable, battery-powered, portable BreatheSuite MDI add-on device and a mobile application based on behavior change strategies – is designed to work with an MDI by attaching to the top of the canister of the patient’s inhaler. The device and mobile app work together to evaluate and “score” a person’s inhaler technique and usage patterns, storing results in the cloud so the person can track and use this information to improve how they use their inhaler. With consent, this information can also be remotely monitored by the person’s healthcare team to promote customizable care plans. By promoting more effective inhaler use and remote patient monitoring (RPM), BreatheSuite aims to improve quality of care and health outcomes while reducing the economic burden associated with these conditions. Medical costs for chronic COPD were estimated to reach $49 billion in 2020, and the annual economic cost of asthma from 2008-2013 was more than $81.9 billion – with medical costs alone accounting for $50.3 billion. “We are extremely excited to have obtained FDA clearance, which is a critical step in achieving our vision of improving the lives of respiratory patients worldwide,” said Brett Vokey, Founder and CEO of BreatheSuite. “The COVID-19 pandemic has underscored that now is the time for remote patient monitoring to take a front seat in providing better, more transparent care for all people with asthma or COPD. With FDA clearance, we are poised to become a leader in providing actionable insights to people with asthma or COPD across the United States.” “By having a real-time way to digitally monitor and provide feedback to patients, we hope to enhance healthcare outcomes,” said Dr. Meshari F. Alwashmi, Chief Scientific Officer, BreatheSuite. “Furthermore, having an objective measure of adherence and technique from each user with asthma and COPD will advance the sphere of knowledge regarding the effectiveness of inhaled medications.” The BreatheSuite device does not interfere with regular MDI usage and can be removed and reattached to a new inhaler with ease. The device is compatible with 90% of MDIs on the market, including those manufactured by GlaxoSmithKline (GSK), Teva and Prasco. In addition to FDA clearance, which is a first for a Newfoundland and Labrador-based company, the BreatheSuite device has also been cleared for sale in Canada. About BreatheSuite BreatheSuite is a Canadian connected health company founded in 2018 to help people with chronic respiratory conditions live longer, healthier lives. The BreatheSuite MDI device is designed to track and train proper inhaler usage, while the BreatheSuite App applies behavior change tactics to improve adherence, and tips on how to improve inhaler technique. BreatheSuite works with leading partners across North America to deliver better care to people with chronic respiratory conditions. For more information visit www.breathesuite.com or contact info@BreatheSuite.com. Contact Details SVM Public Relations and Marketing Communications Jordan Bouclin +1 401-490-9700 jordan.bouclin@svmpr.com Company Website https://www.breathesuite.com/

September 28, 2021 10:00 AM Eastern Daylight Time

Image

Minuteman Press Bethesda Partners with In America Flags to Remember COVID-19 Victims

Minuteman Press International Inc

In America: Remember is a public art exhibition being held at the National Mall that displays 660,000 white flags to honor the people in America who have been lost due to COVID-19. Minuteman Press in Bethesda, Maryland, is a partner for the exhibition, providing printed message cards from people all over the country who are paying tribute to loved ones through the In America website. “We are glad to be able to do our part to help this art exhibition,” says Leslie Klein, owner, Minuteman Press, Bethesda. “Every day, we receive all of the messages that were submitted through the In America website and we print them 8 up on 11 x 17 sheets to create 4.25 x 5.5 cards. Every night, I drop off the finished cards to one of the volunteers, and then they are transcribed onto the flags by another group of volunteers.” Leslie adds, “This is a total team effort and we are proud to be partners in such an important and moving exhibition. Our hearts go out to those who have been lost and their families.” The In America: Remember exhibition was designed by artist Suzanne Brennan Firstenberg. The exhibition is open for public participation now through October 3 rd, 2021. Hours are Weekdays from 10 AM – Sunset and Weekends from 9 AM – Sunset. For more information, visit https://www.inamericaflags.org. Minuteman Press in Bethesda is located at 8210 Wisconsin Ave., Bethesda, MD 20814. For more information, call 301-656-1188 or visit their website: https://minuteman.com/us/locations/md/bethesda Learn more about Minuteman Press products and services at https://minuteman.com Contact Details Minuteman Press International Chris Biscuiti +1 631-249-1370 cbiscuiti@mpihq.com Company Website https://minutemanpressfranchise.com

September 28, 2021 10:00 AM Eastern Daylight Time

Image

CMS Awards Medicare Pricing and Coding Services Contract to Bellese Technologies

Bellese Technologies, LLC

The Centers for Medicare & Medicaid Services (CMS) recently awarded Bellese Technologies the Medicare Payment System Modernization (MPSM) Pricing and Coding Services (PCS) contract. For the past three years, Bellese has worked with CMS, the United States Digital Service (USDS), and stakeholders in the MPSM ecosystem to incrementally modernize the decades-old, mainframe-based legacy payment systems. The Pricing and Coding Services contract is a continuation of the claims pricing modernization work that Bellese accomplished on the preceding contract and includes new work for claims grouping and coding services. Medicare claims payment determination takes numerous variables into consideration, such as fee schedules, price calculations, geographic location, provider type, and payment model participation. The Pricing and Coding Services contract is part of CMS’ holistic approach to give responsive, correct, and accessible services to providers and vendors who support the claims submission process. The modern services will support CMS’ ability to quickly accommodate policy changes and initiatives that determine claims prices. “We’ve been fortunate to be an MPSM pioneer in the application of user research, product management, service design, and the build-out of a cloud-based architectural runway required to support the modern pricer tools,” said Pam Offutt, Bellese Partner and CEO. “Our goal is to give CMS the flexibility they need to quickly provide accurate pricing and coding services to the Medicare community.” John duClos, Bellese Partner and CTO, added that, “the use of a global API specification and a common component strategy contributed to the progressive conversion and modernization of the pricer product. We are excited to build on our success and grateful to continue this important legacy system modernization work with CMS.” ABOUT BELLESE TECHNOLOGIES: Founded in 2009, Bellese Technologies is a human-centered service design company in the Baltimore metro area. Bellese partners with health and human services clients in the public and private sectors. The firm leverages modern technology, human-centered design, and silo-busting collaboration to help its clients expand and accelerate the positive impact they have on society. Currently, Bellese works with the Centers for Medicare & Medicaid Services, supporting price transparency, Medicare payment system modernization, and quality of care initiatives. Bellese holds the GSA IT 70 Schedule and two CMS agile blanket purchase agreements (BPA) — the Medicare Payment System Modernization (MPSM) BPA and the Agile Delivery to Execute Legislative Endeavors-Quality Related Initiatives (ADELE-QRI) BPA. Bellese has been recognized numerous times as a “Top Workplace” by the Baltimore Sun. Visit bellese.io/careers for information on open positions at Bellese. Contact Details Bellese Technologies Shelley Gold, Vice President Client Relations & Growth Strategy +1 410-486-6800 press@bellese.io Company Website https://bellese.io/

September 28, 2021 09:00 AM Eastern Daylight Time

R2 Technologies’ Novel Glacial Rx® System Earns Third FDA Indication and Unique Product Code

R2 Technologies

R2 Technologies Inc. ("R2"), the leader in CryoAesthetic™ medical devices, announces that its revolutionary in-office system, Glacial Rx®, FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation, is now the first and only dermal cooling system FDA-cleared for general dermabrasion, scar and acne scar revision, and tattoo removal, permanently changing the aesthetics industry. “This additional FDA clearance is a huge win, and not an easy feat. It took innovation, dedication, time, and resources,” says Tim Holt, R2 Chief Executive Officer. “It couldn’t have been possible without our amazing team and strategic partners. The clearance had an exceptional outcome in which we went from being part of one classification, among hundreds of other devices, to being placed in our very own FDA-issued product code. This is further proof that our product is so novel, it warrants a completely new category.” “R2 has been at the forefront of the med-esthetics space since inception with its unmatched technology and continues to lead advancements in the industry. We are excited to see the company break boundaries yet again with its latest indication,” says David Present, MD and Cherine Eldumiati Plumaker, R2’s Chairman and Vice Chairman respectively. In conjunction with the commercial launch, R2 looked within its remarkable team of industry veterans, including the inventors of the Glacial Rx technology, Rox Anderson, MD; Dieter Manstein MD, PhD; and Henry Chan, MD, PhD, to create its newly established Scientific Advisory Board. By continuing to have these highly regarded pioneers as an integral part of the company, R2 stands out amongst the competitive medical aesthetics market as an industry frontrunner. “With the appointment of our new Scientific Advisory Board, R2 is tapping into years of knowledge and expertise to launch new groundbreaking innovations, develop a superior product pipeline, and leverage technical insights to secure new clinical indications and expansion opportunities,” says Holt. Launched in March 2021, Glacial Rx’s presence in the U.S. has grown significantly. R2 is continuing to take orders from aesthetic providers who want to offer this revolutionary treatment in-office. To learn more about R2, treatment offerings and providers, visit glacialskin.com and follow the company on LinkedIn. About R2 Technologies Headquartered in Silicon Valley, with a recent expansion in Florida and new Miami-based satellite office, R2 Technologies is a world leader in CryoAesthetic™ medical devices. In 2014, Pansend Life Sciences, LLC and Blossom Innovations, LLC founded R2 Technologies and licensed exclusive intellectual property from Massachusetts General Hospital and Blossom Innovations. In 2019, R2 brought on strategic partner, Huadong Medicine Co., Ltd. In close collaboration with these partners and the brand’s scientiﬁc founders and world-famous luminaries in aesthetic medicine, Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers. Its first innovation, Glacial Rx, was named one of the ‘2021 Launches Doctors are Buzzing About’ by RealSelf, the leading, most trusted source to educate on cosmetic procedures. R2 also won the 2nd Annual Aesthetics Tech Summit LaunchPad SBDC, hosted by Octane, a company committed to making resources, capital, and mentorship available to tech startups. Since inception, R2 has raised $76M in ﬁnancing. Contact Details Linsey Tilbor Rubin +1 732-991-5294 ltilbor@rellmc.com Company Website https://glacialskin.com/

September 28, 2021 08:33 AM Eastern Daylight Time

D8.co to Launch 1-Hour Delivery for Delta-8 THC Products

D8 Holdings, Inc.

D8.co the market leader in hemp-derived Delta-8 THC —today announced it is launching 1-hour delivery for consumer orders throughout the United States. D8.co will deliver their award winning Delta-8 carts, Delta-8 disposables, and Delta-8 gummies to any customer within 1-hour in a 25-mile radius of any professional NFL team. Outside that radius customers will receive next day packages at the latest. “The largest problem we have is fulfillment and delivery,” said Chris Duffield, CEO of D8.co. “Anyone shipping consumer goods knows that all the carriers are a current nightmare. We have shipped thousands of packages priority and the majority show up two or three days late, with far too many getting lost or stolen. If a customer places an order after cutoff on Friday, they have to wait an additional three days. Customers want our products, and they want them immediately.” The first six states D8.co will integrate into their program are Texas, Georgia, Florida, Minnesota, Ohio, and North Carolina. The company will expand into the rest of the U.S immediately, with full integration expected to take approximately 45 days. “We have more than 50 major fulfillment centers locked in that are centrally managed from our cloud technology. Once an order is placed, our customers will receive an email and text where they can track our drivers all the way to delivery,” said Hugh McPherson, EVP of D8.co. D8.co expects to immediately double online sales with the new integration. “We are extremely excited to launch 1-hour delivery,” said Duffield. “We just became the largest cannabis company in the United States, which makes us a prime acquisition target. I’m very proud of our core team and all the hard work everyone has put in to make D8 the number one brand in the market.” About D8.co D8.co is based in Colorado and Miami with satellite offices in Las Vegas and Los Angeles. The company is an assembly of the top hemp and cannabis minds in the country. With backgrounds in extraction, chemistry, manufacturing, marketing, distribution, and legal, the D8 team came together organically around this elusive, but extremely powerful molecule to create a new category of products. More info at www.d8.co. Contact Details D8.co Chris Duffield +1 424-333-2112 chris@d8.co Company Website https://d8.co/

September 23, 2021 12:26 PM Eastern Daylight Time

1 ... 259 260 261 262 263 ... 310

Back